In today’s podcast, we talk to Anne Vaslin Chessex, Global Program Leader at Debiopharm International. In this dynamic chat, we explore Debiopharm’s innovative three-month formulation of Octreotide for acromegaly, highlighting the science, clinical trials, and patient benefits. Gain insights into drug development, patient-centered approaches, future treatment options, and learn how to participate in the clinical trial. Dr. Vaslin Chessex has a PhD in Neurosciences and currently oversees the global strategy for drug development programs in rare diseases. This is a fascinating talk about the science and expertise behind long-acting formulations, patient needs in acromegaly, treatment challenges, and the specifics on the clinical trial design, sites, and recruitment. For those living with acromegaly, the daily challenges of managing their condition can be overwhelming. This podcast explores this new formulation of Octreotide that promises a significant shift in treatment protocols. With insights from Anne, we’ll dive into the details of this innovative approach, how it works, and why it matters for patients.
Read more about the The Oxtend™-03 trial
© 2026, J D Faccinetti. All rights reserved.